You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,256,412


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,256,412
Title: Anti-HIV agent
Abstract:The invention relates to an anti-HIV agent comprising as an effective component a plasma protein of which the polarity of the amino group of the amino acid residue constituting the plasma protein is chemically modified into a negative moiety by a carboxylic acid, for example, by maleic anhydride or succinic anhydride. Plasma proteins modified with dicarboxylic anhydride, which are the effective components of the anti-HIV agent of this invention, inhibit the formation of large cells in mixed culturing of HIV infected cells and non-infected cells as well as the direct infection of helper T cells with HIV. They are very safe compounds and are expected to be applicable to the treatment of HIV infected patients
Inventor(s): Tsunoo; Hajime (Odawara, JP), Takami; Masao (Odawara, JP), Mizumoto; Kenji (Odawara, JP)
Assignee: Meiji Milk Products Co., Ltd. (Tokyo, JP)
Application Number:07/930,349
Patent Claims:1. A composition for inhibiting large cell formation comprising an effective amount of a plasma protein in which the polarity of an amino group of an amino acid residue constituting the plasma protein is chemically modified into a negative moiety and a pharmaceutically acceptable carrier.

2. The composition of claim 1, wherein said amino group of an amino acid residue is modified by a dicarboxylic anhydride.

3. The composition according to claim 2, wherein said dicarboxylic anahydride is maleic anahydride or succinic anhydride.

4. The composition according to claim 1, wherein said plasma protein is a member selected from the group consisting of human serum albumin, human immunoglobulin, human transferrin, human fibrinogen and bovine serum albumin.

Details for Patent 5,256,412

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2010-10-26
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2010-10-26
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2010-10-26
Grifols Biologicals Llc ALBUTEIN albumin (human) Injection 102478 08/15/1978 ⤷  Try a Trial 2010-10-26
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 02/17/1995 ⤷  Try a Trial 2010-10-26
Instituto Grifols, S.a. HUMAN ALBUMIN GRIFOLS albumin (human) Injection 103352 06/11/2003 ⤷  Try a Trial 2010-10-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.